Table 2.
Risk of prostate cancer by baseline total body BMD quartiles in the MrOS cohort
| Total body BMD (g/cm2) |
Quartile Range (g/cm2) |
Number at risk (events) |
Incidence rate (cases per 1000 person-years) |
Unadjusted hazard ratio (95% CI) |
Age-adjusted hazard ratio (95% CI) |
Multivariate hazard ratio (95% CI) * |
|---|---|---|---|---|---|---|
| First Quartile | 0.80–1.09 | 1142 (72) | 12.3 | 1.00 | 1.00 | 1.00 |
| Second Quartile | 1.09–1.17 | 1142 (69) | 11.7 | 0.95 (0.68–1.32) | 0.94 (0.67–1.3) | 0.91 (0.66–1.27) |
| Third Quartile | 1.17–1.25 | 1143 (67) | 11.4 | 0.92 (0.66–1.29) | 0.90 (0.64–1.26) | 0.90 (0.64–1.26) |
| Fourth Quartile | 1.25–2.04 | 1142 (46) | 7.7 | 0.63 § (0.44–0.91) | 0.61 || (0.42–0.89) | 0.59 || (0.40–0.86) |
| P-value for trend | 0.02 | 0.01 | 0.007 | |||
| HR per 1 SD † | 0.88 § | 0.87 § | 0.86 § | |||
| increase in BMD | (0.77–1.00) | (0.76–0.99) | (0.75–0.98) |
*
Adjusted for age, race, BMI, family history of prostate cancer, physical activity, statin use, and calcium intake
†
Total body BMD: SD= 0.12 g/cm2
§
P-value <0.05
||
P-value <0.01